百奥赛图（北京）医药科技股份有限公司 Biosetu (Beijing) Pharmaceutical Technology Co. Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-05-24 08:00
Biocytogen Enters into Antibody Agreement with Merck 2022-04-29 20:00
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene 2022-04-08 21:00
Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany 2022-03-28 21:30
Biocytogen/Eucure Biopharma's CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA 2021-07-07 16:41
Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars 2021-06-23 17:02
1